Literature DB >> 20014026

Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).

Hui Zhao1, Olivier Graf, Nebojsa Milovic, Xiaosong Luan, Markus Bluemel, Markus Smolny, Kurt Forrer.   

Abstract

Since each antibody has its unique physical chemical properties, optimal formulation for one antibody is likely not applicable for the others. To rapidly screen multiple antibody formulations, an automated system was constructed to perform sample preparation, testing, and data management. Using the automatic system, up to 500 liquid formulations can be prepared in deep well microplates and further distributed into standard microplates that can be stored under different stress conditions for degradation studies. In addition, the system can also be used to prepare samples in microplates for different analytical measurements such as UV spectroscopy, turbidity, dynamic light scattering (DLS), SEC-HPLC, RP-HPLC and CEX-HPLC, and automated lab-on-a-chip platform (ALP). The data generated using different techniques in the automatic system were comparable to those of the classical approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014026     DOI: 10.1002/jps.22008

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.

Authors:  Kalli C Catcott; Molly A McShea; Carl Uli Bialucha; Kathy L Miller; Stuart W Hicks; Parmita Saxena; Thomas G Gesner; Mikias Woldegiorgis; Megan E Lewis; Chen Bai; Michael S Fleming; Seth A Ettenberg; Hans K Erickson; Nicholas C Yoder
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

Review 2.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

3.  High-throughput screening of excipients intended to prevent antigen aggregation at air-liquid interface.

Authors:  Sébastien Dasnoy; Nancy Dezutter; Dominique Lemoine; Vivien Le Bras; Véronique Préat
Journal:  Pharm Res       Date:  2011-03-12       Impact factor: 4.200

4.  Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule.

Authors:  David Ouellette; Chris Chumsae; Anca Clabbers; Czeslaw Radziejewski; Ivan Correia
Journal:  MAbs       Date:  2013-04-22       Impact factor: 5.857

5.  Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates.

Authors:  Andrea Hawe; Wendy L Hulse; Wim Jiskoot; Robert T Forbes
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

6.  Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Authors:  Aran F Labrijn; Joyce I Meesters; Patrick Priem; Rob N de Jong; Ewald T J van den Bremer; Muriel D van Kampen; Arnout F Gerritsen; Janine Schuurman; Paul W H I Parren
Journal:  Nat Protoc       Date:  2014-09-25       Impact factor: 13.491

7.  Stability enhancement in a mAb and Fab coformulation.

Authors:  Hongyu Zhang; Paul A Dalby
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

8.  Quantification of natural abundance NMR data differentiates the solution behavior of monoclonal antibodies and their fragments.

Authors:  David Ban; Cory T Rice; Mark A McCoy
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 9.  Advancements in the co-formulation of biologic therapeutics.

Authors:  Veeren M Chauhan; Hongyu Zhang; Paul A Dalby; Jonathan W Aylott
Journal:  J Control Release       Date:  2020-08-14       Impact factor: 9.776

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.